APA (7th ed.) Citation

Allouchery, M., Beuvon, C., Pérault-Pochat, M., Roblot, P., Puyade, M., & Martin, M. (2022). Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review. Cancers, 14(4), 955. https://doi.org/10.3390/cancers14040955

Chicago Style (17th ed.) Citation

Allouchery, Marion, Clément Beuvon, Marie-Christine Pérault-Pochat, Pascal Roblot, Mathieu Puyade, and Mickaël Martin. "Safety of Immune Checkpoint Inhibitor Resumption After Interruption for Immune-Related Adverse Events, a Narrative Review." Cancers 14, no. 4 (2022): 955. https://doi.org/10.3390/cancers14040955.

MLA (9th ed.) Citation

Allouchery, Marion, et al. "Safety of Immune Checkpoint Inhibitor Resumption After Interruption for Immune-Related Adverse Events, a Narrative Review." Cancers, vol. 14, no. 4, 2022, p. 955, https://doi.org/10.3390/cancers14040955.